Received Mar 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| FLU4 | INFLUENZA (SEASONAL) (FLUZONE QUADRIVALENT) | SANOFI PASTEUR | UNK | UNK | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
Soreness at injection site; The patient has not yet received the second dose; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 62-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis and Influenza vaccine inact split 4v (Fluzone quadrivalent) for prophylaxis. On 25-NOV-2019, the patient received the 1st dose of Shingrix (unknown arm). On an unknown date, the patient did not receive the 2nd dose of Shingrix. On 25-NOV-2019, the patient received Fluzone quadrivalent (unknown arm). On an unknown date, an unknown time after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced injection site pain (Verbatim: Soreness at injection site) and incomplete course of vaccination (Verbatim: The patient has not yet received the second dose). The outcome of the injection site pain was unknown and the outcome of the incomplete course of vaccination was not applicable. It was unknown if the reporter considered the injection site pain to be related to Shingrix. It was unknown if the company considered the injection site pain to be related to Shingrix. Additional Information: GSK Receipt Date: 13-MAR-2025 The patient self-reported this case for himself. The patient received the first dose of Shingrix and had not yet received the second dose till the time of reporting, which led to an incomplete course of vaccination. The patient also received Fluzone Quad vaccine at the same time. The patient believed the vaccines were given in different arms. The patient had soreness at the injection site after receiving Shingrix. No other conditions were provided. It was unknown if the reporter considered the injection site pain to be related to Fluzone Quad vaccine.